(Q24236699)

1

0 references

Sabin Smith

2

0 references

Robert H Granger

4

0 references

Richard Wood-Baker

Cochrane Database of Systematic Reviews

5

0 references

publication date

10 November 2010

0 references

published in

0 references

cites work

Clinical efficacy of anti-pneumococcal vaccination in patients with COPD.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Response to pneumococcal vaccine in chronic obstructive lung disease—The effect of ongoing, systemic steroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Treatment of acute exacerbations of chronic bronchitis: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal Disease and its Prevention with Polyvalent Pneumococcal Polysaccharide Vaccines-A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Immunization of elderly people with polyvalent pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

The clinical effectiveness of pneumococcal vaccination: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Inefficacy of pneumococcal vaccine in a high-risk population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal vaccine. Efficacy and associated cost savings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

21 January 2018

Immunization of adults.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal vaccine in the United States. A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Effectiveness of pneumococcal polysaccharide vaccine in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Variation in tertiary prevention and health service utilization among the elderly: the role of urban-rural residence and supplemental insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal vaccination for patients with COPD: current practice and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumococcal vaccine: clinical efficacy and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Protective Efficacy of Pneumococcal Polysaccharide Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Therapeutic algorithm for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Pneumonic vs nonpneumonic acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

The Pneumococcal Vaccine After 15 Years of Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumonia in old age; active immunization against pneumonia with pneumonococcus polysaccharide; results of a six year study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal vaccines and public health policy. Consequences of missed opportunities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

A cost-benefit analysis of immunization for pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Placebo controlled pneumococcal immunization in patients with bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal infection after vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Cost effectiveness of vaccination against pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

A Reassessment of Pneumococcal Vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal vaccine failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

New strains of bacteria and exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal Vaccine in the Institutionalized Elderly: Review of Past and Recent Studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Efficacy of pneumococcal polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Benefits of influenza vaccine in US elderly--appreciating issues of confounding bias and precision

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Field trial of an inactivated Mycoplasma pneumoniae vaccine. I. Vaccine efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

COPD is associated with increased mortality in patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal vaccine in elderly patients with COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal vaccine efficacy in selected populations in the United States

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Pneumococcal vaccine and patients with chronic lung disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

Cost effectiveness of vaccination against pneumococcal pneumonia: an update

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021

The Clinical Effectiveness of Pneumococcal Vaccine in the Elderly

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001390.PUB3

7 January 2021